SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2011
COMPLETE GENOMICS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
2071 Stierlin Court
Mountain View, California 94043
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650) 943-2800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
This Current Report on Form 8-K/A is being filed as an amendment to the Current Report on Form 8-K filed on June 27, 2011 (the Original Report), by Complete Genomics, Inc. (the Company), in order to supplement the information disclosed under Item 5.07 Submission of Matters to a Vote of Security Holders regarding the results of voting at the Companys Annual Meeting of Stockholders held on June 22, 2011 (the 2011 Annual Meeting). Except as expressly set forth herein, this amendment does not amend, modify or update the disclosures contained in the Original Report.
|Item 5.07||Submission of Matters to a Vote of Security Holders.|
At the Companys 2011 Annual Meeting, its stockholders selected, on an advisory basis, the holding of an advisory vote on the compensation of the Companys named executive officers every three years. Based on the Board of Directors recommendation and the voting results for this proposal at the 2011 Annual Meeting, the Companys Board of Directors has determined that the Company will hold future stockholder advisory votes on the compensation of its named executive officers every third year until the next required advisory vote of the Companys stockholders on the frequency of stockholder advisory votes on executive compensation, or the Board of Directors otherwise determines that a different frequency for such advisory vote is in the best interests of the stockholders of the Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: November 3, 2011||COMPLETE GENOMICS, INC.|
/s/ Ajay Bansal
|Title:||Chief Financial Officer|